Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumours in cell culture.

Human pancreatic growth hormone releasing factors (hpGRF(1-40) and hpGRF(1-44) significantly stimulated GH secretion when added to cell cultures of human somatotrophic pituitary tumours for 2 h. There was little difference in potency between the two peptides, and the response of different tumours varied, ranging from 30% to 500% increases in GH secretion over control levels. This stimulatory effect was blocked by somatostatin (SRIF) and bromocriptine.

Impaired growth hormone response to human pancreatic growth hormone releasing factor [GRF(1-44)] in type 2 (non-insulin-dependent) diabetes.

Human pancreatic growth hormone releasing factor [GRF(1-44)] is the largest molecule of several peptides recently isolated from pancreatic tumours associated with acromegaly. It has been shown to stimulate the release of growth hormone in normal subjects and provides a safe and reliable tool for examining growth hormone release. A study was conducted to examine the release of growth hormone in patients with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes.

Vagal origin of substance P-containing nerves in the guinea pig lung.

This study reports on the possible origin and putative sensory nature of substance P-containing fibres in the lung. Following vagal ligation experiments, carried out on adult guinea pigs, the vagi, nodose ganglia and lungs were investigated by immunocytochemistry and radioimmunoassay. After ligation the lung showed a marked depletion of substance P-immunoreactivity; concomitantly there was an accumulation of immunoreactive material proximal to the ligature, indicating a peripheral direction of the peptide axonal flow.